[go: up one dir, main page]

WO2022010024A1 - Composition à base de plantes pour soulager ou traiter la dermatite atopique, comprenant des ingrédients composites naturels, et son procédé de préparation - Google Patents

Composition à base de plantes pour soulager ou traiter la dermatite atopique, comprenant des ingrédients composites naturels, et son procédé de préparation Download PDF

Info

Publication number
WO2022010024A1
WO2022010024A1 PCT/KR2020/010477 KR2020010477W WO2022010024A1 WO 2022010024 A1 WO2022010024 A1 WO 2022010024A1 KR 2020010477 W KR2020010477 W KR 2020010477W WO 2022010024 A1 WO2022010024 A1 WO 2022010024A1
Authority
WO
WIPO (PCT)
Prior art keywords
parts
weight
distillate
hot water
water extract
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2020/010477
Other languages
English (en)
Korean (ko)
Inventor
김성현
노성일
이육노
오병래
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biokos Co Ltd
Original Assignee
Biokos Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020200083344A external-priority patent/KR102490086B1/ko
Application filed by Biokos Co Ltd filed Critical Biokos Co Ltd
Priority claimed from KR1020200098893A external-priority patent/KR102585932B1/ko
Publication of WO2022010024A1 publication Critical patent/WO2022010024A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232—Angelica
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/489—Sophora, e.g. necklacepod or mamani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Definitions

  • the present invention relates to an oriental medicine composition for the improvement or treatment of atopic dermatitis containing a natural complex component and a method for manufacturing the same, and more specifically, to a composition containing a natural complex ingredient, which has strong anti-inflammatory and antioxidant activity, and is toxic to keratinocytes. It relates to an oriental medicine composition suitable for use in the improvement or treatment of atopic dermatitis and a method for manufacturing the same, since the use of chemical preservatives and additives that can cause skin irritation can be avoided due to excellent long-term storage stability.
  • Atopic dermatitis is a chronic dermatitis that occurs frequently in people with a genetic predisposition to cause eczema, hayfever, asthma, allergy, etc. It is called fetal fever and starts as infantile eczema and has a chronic, recurrent course.
  • atopic dermatitis Today, the general treatment of atopic dermatitis is aimed at controlling pruritus and preventing the occurrence of secondary lesions, and depending on the drug administration method, an external method, an oral method, and an immunization method are used.
  • external methods a method of washing the skin, a method of applying a steroid-based ointment, and a method of applying a moisturizer are used.
  • steroids are a kind of adrenal corticosteroid, and although the effect is very fast, various side effects such as atrophy of the skin and the possibility of growth retardation in pediatric patients when used for a long period of time are problematic.
  • Moisturizer refers to applying cosmetics to supply and maintain moisture to dry skin.
  • Antihistamines, steroid-based drugs, or herbal medicines are mainly used for the treatment of atopic dermatitis, which is mainly used as an oral method.
  • Immunity is the process of adjusting or inducing the surrounding environment to naturally develop the body's immunity.
  • the over-the-counter composition contains conventionally developed herbal extracts or herbal preparations to treat atopic diseases and other skin diseases (psoriasis, eczema). When discontinuing use, serious side effects for dilated disease and tertiary bacterial infection may develop.
  • the characteristics of the immune system in children and adults can be related to the development and pathological characteristics of atopy. 70-80% of newborns in Korea experience fetal fever. Most of them naturally tend to be treated as they enter childhood. However, according to some reports, 20-30% of them progress to atopy in children. This phenomenon is a natural change of the immune system, that is, as the specific immunity of infancy enters childhood, the natural immunity is restored and atopy is cured.
  • the immunological characteristic of this period can be seen as the period when natural immunity is actively growing. In other words, it is a process in which the natural immune system grows as children experience fever-like symptoms. Therefore, it is not advisable to misuse or abuse antipyretics or antibiotics when children have cold or fever symptoms. In adults, this is a period in which both the natural and specific immunity are mature to some degree. In other words, whether healthy or not, the immune system is fixed to some degree.
  • heat poison not only causes skin abnormalities, but also causes various complications by lowering the body's immunity, they argue that it is necessary to find the cause of atopic dermatitis and treat it fundamentally rather than just treating the symptoms.
  • basic treatment such as releasing heat poison that causes atopic dermatitis and increasing self-reliance to fight allergies can prevent recurrence.
  • Inflammatory cells are mainly cells involved in secondary reactions such as macrophages and eosinophils. It is believed to have penetrated into This disease is strongly associated with the TH1/TH2 immune response.
  • naive T cells are exposed to interleukin (IL)-12, IL-18, or IL-4 to differentiate into TH1 or TH2 cells.
  • TH1 cells secrete inflammatory cytokines interferon-gamma (IFN- ⁇ ) and tumor necrosis factor-alpha (TNF- ⁇ ) and suppress TH2, whereas TH2 cells contain IL-4, IL It secretes -5 and IL-13 and suppresses TH1 response.
  • IFN- ⁇ interferon-gamma
  • TNF- ⁇ tumor necrosis factor-alpha
  • TH2 cells contain IL-4, IL It secretes -5 and IL-13 and suppresses TH1 response.
  • IL-8 is a cytokine mainly associated with inflammation, and IL-8, which is known
  • This research team researches and tests various medicinal herbs and natural materials used in oriental medicine, and when extracting natural ingredients with hot water, cooling and recovering the distillation components that are volatilized at a certain temperature or higher produces a hydrothermal distillation fraction rich in essential oils, aromatics and antioxidants. It was found that it can be secured, and the present invention was completed by compounding a composition showing the best efficacy for the improvement or treatment of atopic skin diseases.
  • the problem to be solved by the present invention is to provide an oriental medicine composition useful for the improvement or treatment of atopic dermatitis because it contains natural complex ingredients and has excellent anti-inflammatory and antioxidant activity and no side effects.
  • Another object to be solved by the present invention is to provide a method for preparing an oriental medicine composition for improving or treating atopic dermatitis as described above.
  • An oriental medicine composition for improving or treating atopic dermatitis is 3-5 parts by weight of high ginseng, 3-5 parts by weight of ginseng, 4-6 parts by weight of gold, 4-6 parts by weight of white paper It contains the distillate of the hot water extract of a mixture comprising parts, presbytery, 3-5 parts by weight, haedongpi, 3-5 parts by weight, and softwood, 5-7 parts by weight.
  • composition may further include the hot water extract in an amount of 10-30 parts by weight based on 70-90 parts by weight of the distillate.
  • the oriental medicine composition for improving or treating atopic dermatitis for solving the above problems is 3-5 parts by weight of a distillate of hot ginseng extract, 3-5 parts by weight of a distillate of hot water extract of Gossam, 4-6 parts by weight of distillate of golden hot water extract, 4-6 parts by weight of distillate of white paper hot water extract, 3-5 parts by weight of distillate of presbytery hot water extract, 3-5 parts by weight of distillate of haedongpi hot water extract and Yeongyo hot water 5-7 parts by weight of the distillate of the extract.
  • the composition comprises 4-6 parts by weight of distillate of Duchung hot water extract, 4-6 parts by weight of distillate of peony hot water extract, 1-3 parts by weight of distillate of Mokhyang hot water extract, and 1-3 parts by weight of distillate of Angelica hot water extract.
  • distillate of dermis hot water extract 1-3 parts by weight of distillate of dermis hot water extract, 4-6 parts by weight of distillate of fennel hot water extract, 5-7 parts by weight of distillate of health hot water extract, 3-5 parts by weight of distillate of husk hot water extract, chrysanthemum 4-6 parts by weight of the distillate of the hot water extract, 4-6 parts by weight of the distillate of the ginseng root hot water extract, 4-6 parts by weight of the distillate of the Zimo hot water extract, 1-3 parts by weight of the distillate of the Gokgisaeng hot water extract, Hwangbaek hot water 5-7 parts by weight of distillate of extract, 3-5 parts by weight of distillate of Gobon hot water extract, 3-5 parts by weight of distillate of rhubarb hot water extract, 3-5 parts by weight of distillate of gardenia hot water extract, Tobongryeong hot water extract It may further include at least one selected from the group consisting of 3-5 parts by weight of the distillate and 5-7
  • the method of manufacturing an oriental medicine composition for improvement or treatment of atopic dermatitis is (a) 3-5 parts by weight of high ginseng, 3-5 parts by weight of ginseng, 4-6 parts by weight of gold parts, 4-6 parts by weight of white paper, 3-5 parts by weight of presbytery, 3-5 parts by weight of haedongpi, and 5-7 parts by weight of yeonkyo to obtain an extract by hot water extraction, and (b) heating the extract and cooling the resulting vapor to obtain a distillate.
  • the manufacturing method may further include (c) mixing 10-30 parts by weight of the extract remaining after the heating to 70-90 parts by weight of the distillate.
  • step (a) the high ginseng, gooseberry, gold, white paper, presbytery, haedongpi and Yeongyo are put in purified water and heated to 80-100 ° C. for 8-48 hours using an extractor, and the heated It may include the step of obtaining the extract by filtration.
  • the step (b) may include heating the extract to 90-100° C. and liquefying the steam produced by 4-10° C. cooling water pipe, and liquefying the liquefied product at 8,000-14,000 rpm and 2- It may include the step of removing the solid by centrifugation at 8 ° C. for 10-50 minutes, and taking the supernatant to obtain the distillate.
  • step (a) 4-6 parts by weight of duchung, 4-6 parts by weight of peony, 1-3 parts by weight of mulberry, 1-3 parts by weight of angelica, 1-3 parts by weight of dermis, 4-6 parts by weight of fennel , Health 5-7 parts by weight, Hucchini 3-5 parts by weight, Chrysanthemum 4-6 parts by weight, Root Root 4-6 parts by weight, Zinc 4-6 parts by weight, Grain ginseng 1-3 parts by weight, Hwangbaek 5-7 parts by weight , 3-5 parts by weight of Gobon, 3-5 parts by weight of rhubarb, 3-5 parts by weight of gardenia, 3-5 parts by weight of Tobongryeong and 5-7 parts by weight of Sambaekcho by further mixing at least one selected from the group consisting of hot water extraction can
  • a method of manufacturing an oriental medicine composition for improvement or treatment of atopic dermatitis is (a) hot water extraction of Gosam, Goehwa, Gold, White paper, Hwangbaek, Gobon, Haedongpi and Yeongyo, respectively.
  • each extract (b) heating each extract to cool the produced vapor to obtain each distillate, and (c) 3-5 parts by weight of the distillate of high ginseng, distillate 3 of Gohwa -5 parts by weight, 4-6 parts by weight of distillate of gold, 4-6 parts by weight of distillate of white paper, 3-5 parts by weight of distillate of presbytery, 3-5 parts by weight of distillate of thawed blood and 5 parts of distillate of Yeongyo -7 parts by weight are mixed with each other.
  • the step (a) is a step of putting each of the dried ginseng, Gohwa, gold, white paper, presbytery, haedongpi and Yeongyo in purified water and heating it to 80-100 ° C. for 8-48 hours using an extractor, and the heated It may include the step of obtaining each extract by filtration.
  • step (b) is a step of liquefying the steam produced by heating each extract to 90-100 °C with a cooling water pipe of 4-10 °C, and 8,000-14,000 rpm and 2-8 °C of the liquefied It may include the step of removing the solid content by centrifugation for 10-50 minutes and taking the supernatant to obtain each of the distillates.
  • step (c) 4-6 parts by weight of distillate of duchung, 4-6 parts by weight of distillate of peony, 1-3 parts by weight of distillate of mulberry, 1-3 parts by weight of distillate of angelicae, dermis 1-3 parts by weight of distillate, 4-6 parts by weight of distillate of fennel, 5-7 parts by weight of distillate of health, 3-5 parts by weight of distillate of husk, 4-6 parts by weight of distillate of chrysanthemum, garlic root 4-6 parts by weight of the distillate, 4-6 parts by weight of the distillate of Zimo, 1-3 parts by weight of the distillate of Gokgi-saeng, 5-7 parts by weight of the distillate of Hwangbaek, 3-5 parts by weight of the distillate of Gobon; At least one selected from the group consisting of 3-5 parts by weight of distillate of rhubarb, 3-5 parts by weight of distillate of gardenia, 3-5 parts by weight of distillate of Tobongryeong
  • the method for preparing an oriental medicine composition for improving or treating atopic dermatitis may further include further purifying the obtained distillate using an ultrafiltration membrane or chromatography.
  • the density of the above-described distillate or supernatant may be approximately 1 kg/L, that is, approximately or substantially the same as the density of purified water. Accordingly, 'parts by weight', which is the content unit of the above-described distillate or supernatant, may be substantially the same as 'parts by volume'.
  • the oriental medicine composition according to the embodiments of the present invention contains natural complex ingredients, so it has strong anti-inflammatory and antioxidant activity, is non-toxic to keratinocytes, and has excellent long-term storage stability, which can cause skin irritation. Since the use of preservatives and additives can be avoided, it is suitable for use in the improvement or treatment of atopic dermatitis.
  • 1 is a graph measuring the toxicity to keratinocyte cells of the oriental medicine composition of the present invention according to an experimental example of the present invention.
  • Figure 2 is a graph measuring the amount of nitric oxide (NO) production reduction activity of the oriental herbal composition of the present invention according to an experimental example of the present invention.
  • FIG. 3 is a graph measuring the reduction activity of the inflammatory cytokines (IL-8, TNF- ⁇ ) of the herbal composition of the present invention according to an experimental example of the present invention.
  • the term 'prevention' refers to inhibiting the occurrence of a disease or disease in an individual who has never been diagnosed with a disease or disease, but may be afflicted with such disease or disease.
  • 'treatment' or 'improvement' refers to (a) inhibition of the development (exacerbation) of a disease or disease, (b) alleviation of the disease or disease, or (c) elimination of the disease or disease in an individual.
  • the term 'subject' refers to a mammal, including a human, having a disease whose symptoms can be improved by administering the composition of the present invention.
  • the oriental medicinal composition of the present invention has an improvement or therapeutic effect on atopic dermatitis, and in the present specification, 'atopic dermatitis' is used in a broad sense including atopic dermatitis, skin disease, psoriasis, eczema, itching, and the like.
  • the herbal composition of the present invention may be composed of one or more formulations selected from the group consisting of a liquid extract, a concentrated liquid extract, a freeze-dried powder, and a spray-dried powder.
  • the herbal composition of the present invention is a transdermal absorbent (external skin ointment), water soap, soap, essence, gel, liquid detergent, lotion, foam, soft water, lotion, cleansing foam, cleansing lotion, cleansing cream, pack, massage cream , emollient cream, emollient lotion, lotion essence, astringent, water-soluble liquid, foundation, makeup base, body lotion, astringent lotion, softening lotion, nourishing lotion, treatment, skin lotion, milk It may be one or more formulations selected from the group consisting of lotions, nutritional lotions, nutritional essences, oil-in-water (O/W) types and water-in-oil (W/O) types.
  • the herbal composition of the present invention may be included in an amount of 0.005-95 wt% based on the total composition of the formulation.
  • An herbal composition was prepared in the same manner as in Example 1, except that 3 L of the hot water extract remaining after heating in Example 1 was mixed with 7 L of the distillate and centrifuged.
  • daffodil As a raw material for herbal medicines, 50 g of daffodil, 50 g of peony, 20 g of mulberry, 20 g of angelica, 20 g of ginseng, 50 g of fennel, 60 g of health, 40 g of green peppercorns, 50 g of chrysanthemum, 50 g of ginseng root, 50 g of ginseng root, 20 g of ginseng g, Hwangbaek 60 g, Gobon 40 g, and Sambaekcho 60 g, except that an oriental medicine composition was prepared in the same manner as in Example 1 above.
  • each raw material After thoroughly washing the raw materials of medicinal herbs of ginseng, Gohwa, gold, white paper, presbytery, haedongpi and Yeongyo with purified water, each raw material is separately put into a boiling water still filled with 20 L of purified water and heated at about 80-100 ° C for 30 hours. Each hot water extract was obtained. Herbal medicines used for extraction were removed by filtration, and each distillate was obtained using a cooling water tube of about 4-10 °C while heating each hot water extract to about 90-100 °C. Each distillate was centrifuged at 12,000 rpm and 4° C. for 30 minutes to remove solids, and each supernatant was collected.
  • An oriental medicine composition was prepared by mixing 0.4 L of high ginseng supernatant, 0.4 L of Goehwa supernatant, 0.5 L of golden supernatant, 0.5 L of white paper supernatant, 0.4 L of presbytery supernatant, 0.4 L of Haedongpi supernatant and 0.6 L of Yeongyo supernatant.
  • the toxicity of the oriental herbal composition of the present invention to keratinocytes was tested as follows.
  • human keratinocyte cell line HaCaT
  • DMEM Dulbecco's modified Eagle's medium
  • FBS Fetal bovine serum
  • the medium was changed to a serum-free medium and cultured for 16-24 hours, and then the medium containing the composition of the above example was exchanged. After 48 hours, it was exchanged with a medium containing 10% MTT (Tetrazolium-based colorimetric) solution. After incubation for 2-4 hours, the medium was removed and the precipitate remaining under the culture dish was dissolved with DMSO (dimethyl sulfoxide).
  • DMSO dimethyl sulfoxide
  • the oriental medicine composition of the present invention does not show toxicity to keratinocytes.
  • DMEM Dulbecco's modified Eagle's medium
  • FBS fetal bovine serum
  • penicillin and streptomycin 100 unit/ml penicillin and streptomycin at a concentration of 1 ⁇ 10 6 cell/ml in a 96-well plate. Inoculated and incubated overnight at 37 °C, 5% CO 2 . The next day, the medium was removed and replaced with a fresh medium, and cells were treated with 50 ⁇ l of the composition of the above example.
  • a medium containing 50 ⁇ l (1 ⁇ g/ml) of LPS (lipopolysaccharide) was treated and incubated in an incubator (5% CO 2 , 37 ° C.) for 24 hours.
  • PBS phosphate buffered saline
  • Griess reagent I NBD solution
  • Griess reagent II Sulfaniliamide solution
  • the concentration of nitric oxide (NO) was calculated using a standard curve (0-100 ⁇ M) of sodium nitrite.
  • the oriental herbal compositions of the present invention have excellent antioxidant and anti-inflammatory activity because they reduced the amount of NO produced by LPS by 40-50% or more.
  • the anti-inflammatory activity of the herbal composition of the present invention was measured as follows.
  • RAW 264.7 cells cultured as in the above experimental example were first treated with the composition of the above example, then LPS (lipopolysaccharide) was treated at a concentration of 1 ⁇ g/ml and cultured for 24 hours, the supernatant was recovered and IL-8 using an ELISA kit. (interleukin-8) was measured. After reacting using an antibody for detection bound to Avidin, absorbance was measured at 450 nm with a microplate reader, and phosphate buffered saline (PBS) was used as a control.
  • PBS phosphate buffered saline
  • the secretion amount of IL-8 and the expression level of TNF- ⁇ were as shown in FIG. 3, and as shown in FIG. 3, the oriental medicine compositions of the present invention showed the production of IL-8 and TNF- ⁇ , which are inflammatory cytokines promoted by LPS. It can be seen that there is excellent anti-inflammatory activity because it is reduced by more than 40-50%.
  • 0.1 ml of the composition of the above example was smeared on Letheen agar and left at 30° C. for 48 hours to check whether or not bacteria were propagated. It was checked whether The presence of bacteria and fungi was confirmed immediately after preparation of the composition of the above example and after leaving it alone.
  • the oriental herbal composition of the present invention has excellent long-term storage stability because microorganisms do not propagate even when stored for a long period at room temperature without a separate preservative, so chemical preservatives and additives that may cause skin irritation can be omitted.
  • the present invention can be used in the industrial field related to an oriental medicine composition for improving or treating atopic dermatitis and a method for manufacturing the same.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne une composition à base de plantes pour soulager ou traiter la dermatite atopique, et son procédé de préparation, et plus spécifiquement, une composition à base de plantes appropriée pour une utilisation dans le soulagement ou le traitement de la dermatite atopique, qui comprend un distillat d'un extrait d'eau chaude d'un mélange comprenant de 3 à 5 parties en poids de Sophorae radix, 3 à 5 parties en poids de Sophorae Flos, 4 à 6 parties en poids de Scutellariae Radix, 4 à 6 parties en poids d'Angelica dahurica Radix, 3 à 5 parties en poids d'Aloe barbadensis, 3 à 5 parties en poids de Kalopanax pictus, et 5 à 7 parties en poids de Forsythiae fructus, et présente de puissantes activités anti-inflammatoires et antioxydantes et aucune toxicité vis-à-vis des kératinocytes, et a une excellente stabilité au stockage à long terme, ce qui élimine ainsi la nécessité d'utiliser des conservateurs chimiques et des additifs qui peuvent provoquer une irritation de la peau. En outre, la présente invention concerne un procédé de préparation de la composition à base de plantes.
PCT/KR2020/010477 2020-07-07 2020-08-07 Composition à base de plantes pour soulager ou traiter la dermatite atopique, comprenant des ingrédients composites naturels, et son procédé de préparation Ceased WO2022010024A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR1020200083344A KR102490086B1 (ko) 2020-07-07 2020-07-07 천연 복합성분을 함유하는 아토피 피부염의 개선 또는 치료용 조성물 및 그 제조 방법
KR10-2020-0083344 2020-07-07
KR10-2020-0098893 2020-08-07
KR1020200098893A KR102585932B1 (ko) 2020-08-07 2020-08-07 천연 복합성분을 함유하는 아토피 피부염의 개선 또는 치료용 조성물 및 그 제조 방법

Publications (1)

Publication Number Publication Date
WO2022010024A1 true WO2022010024A1 (fr) 2022-01-13

Family

ID=79553290

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2020/010477 Ceased WO2022010024A1 (fr) 2020-07-07 2020-08-07 Composition à base de plantes pour soulager ou traiter la dermatite atopique, comprenant des ingrédients composites naturels, et son procédé de préparation

Country Status (1)

Country Link
WO (1) WO2022010024A1 (fr)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0995451A (ja) * 1995-09-19 1997-04-08 Epuson Medical Kk アトピー性皮膚炎の治療薬剤
KR100879032B1 (ko) * 2007-05-09 2009-01-15 (주)한스킨 천연 항균 및 항염 효과가 있는 항균, 항산화 및 항염억제제 및 이를 함유하는 화장료 조성물
KR20110104625A (ko) * 2010-03-17 2011-09-23 우석대학교 산학협력단 아토피 피부염 예방 및 개선효과를 나타내는 황금 가수분해 추출물의 제조방법 및 이를 이용하여 제조된 화장품
KR20120032311A (ko) * 2010-09-28 2012-04-05 한국 한의학 연구원 생약 추출물 또는 이의 유산균 발효물을 포함하는 아토피 피부염의 예방 또는 치료용 조성물
KR20120061528A (ko) * 2010-12-03 2012-06-13 이항종 복합추출물을 함유하는 피부질환 개선용 조성물 및 이를 이용한 화장료
KR20130030491A (ko) * 2011-09-19 2013-03-27 최양원 아토피 및 여드름 치료용 생약조성물
KR20190014774A (ko) * 2017-08-03 2019-02-13 김현숙 아토피성 피부염 개선제 및 이의 제조방법

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0995451A (ja) * 1995-09-19 1997-04-08 Epuson Medical Kk アトピー性皮膚炎の治療薬剤
KR100879032B1 (ko) * 2007-05-09 2009-01-15 (주)한스킨 천연 항균 및 항염 효과가 있는 항균, 항산화 및 항염억제제 및 이를 함유하는 화장료 조성물
KR20110104625A (ko) * 2010-03-17 2011-09-23 우석대학교 산학협력단 아토피 피부염 예방 및 개선효과를 나타내는 황금 가수분해 추출물의 제조방법 및 이를 이용하여 제조된 화장품
KR20120032311A (ko) * 2010-09-28 2012-04-05 한국 한의학 연구원 생약 추출물 또는 이의 유산균 발효물을 포함하는 아토피 피부염의 예방 또는 치료용 조성물
KR20120061528A (ko) * 2010-12-03 2012-06-13 이항종 복합추출물을 함유하는 피부질환 개선용 조성물 및 이를 이용한 화장료
KR20130030491A (ko) * 2011-09-19 2013-03-27 최양원 아토피 및 여드름 치료용 생약조성물
KR20190014774A (ko) * 2017-08-03 2019-02-13 김현숙 아토피성 피부염 개선제 및 이의 제조방법

Similar Documents

Publication Publication Date Title
KR101205097B1 (ko) 아토피 피부염 예방 및 개선효과를 나타내는 알로에 발효 및 가수분해 추출물의 제조방법 및 이를 이용하여 제조된 화장품
WO2006123887A1 (fr) Composition contenant des plantes medicinales destinee au traitement de la dermite atopique
CN113855718A (zh) 青蒿提取物及其应用
KR20090023236A (ko) 생약재 발효산물을 포함하는 아토피성 피부염 치료 및/또는예방용 조성물
CN109316417A (zh) 一种抗衰老中药组合物发酵原浆及制备和应用
KR20090017182A (ko) 저먼 카모마일 오일을 함유하는 아토피성 피부염 완화제
CN113679765A (zh) 白鲜皮提取物及其应用
CN113521152B (zh) 抗皮炎组合物及其制备方法和用途
WO2018105926A1 (fr) Composition anti-allergique contenant un extrait d'herbe médicinale composite fermenté par des lactobacilles à titre de principe actif
KR20220019161A (ko) 천연 복합성분을 함유하는 아토피 피부염의 개선 또는 치료용 한방 조성물 및 그 제조 방법
CN108014123A (zh) 臭氧化中草药、中药制剂提取物
CN112386665B (zh) 天然原料的发酵液以及其用于制备抑制过敏反应或提升免疫力的组合物的用途
CN101972334B (zh) 防治婴幼儿湿疹的中药制剂及其制备方法
WO2022010024A1 (fr) Composition à base de plantes pour soulager ou traiter la dermatite atopique, comprenant des ingrédients composites naturels, et son procédé de préparation
KR102537948B1 (ko) 천연 복합성분을 함유하는 아토피 피부염의 개선 또는 치료용 조성물 및 그 제조 방법
KR101026873B1 (ko) 항염 활성을 갖는 혼합 생약재 추출물 및 이를 함유하는화장료 조성물
KR102144566B1 (ko) 택란 추출물을 유효성분으로 포함하는 아토피 피부염의 예방 또는 치료용 조성물
KR102490086B1 (ko) 천연 복합성분을 함유하는 아토피 피부염의 개선 또는 치료용 조성물 및 그 제조 방법
KR102537982B1 (ko) 생화학적 미네랄 재조합 복합성분을 함유하는 중증 피부질환의 개선 또는 치료용 조성물 및 그 제조 방법
KR20220132478A (ko) 생약 지표성분을 함유하는 아토피 피부염의 개선 또는 치료용 조성물 및 그 제조 방법
CN117815129A (zh) 富含脯氨酸小蛋白基因sprr2a的表达促进剂
CN117100801B (en) Medicinal composition for resisting atopic dermatitis, and preparation method and application thereof
KR102034436B1 (ko) 베트남 후피향 추출물을 포함하는 아토피 피부염 치료 및 예방용 조성물
CN105749159B (zh) 治疗银屑病中药在制备治疗多发性硬化症药物中的应用
CN118903355B (zh) 一种治疗痤疮的药物组合物及其制备方法和用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20944555

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20944555

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 20944555

Country of ref document: EP

Kind code of ref document: A1